$RVMD News

ESMO26: Clinical progress shifts a historically difficult pancreatic cancer landscape

Revolution Medicines (RVMD) Stock Looks Above Fair Value Today

Revolution Medicines (RVMD) Following New Pancreatic Cancer Data Looks Undervalued

Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026

Here’s How Much You Would Have Made Owning Revolution Medicines Stock In The Last 5 Years

Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy

Revolution Medicines Presents Exploratory Subgroup Analyses From Phase 3 RASolute 302 Trial, As Late-Breaking Abstract At ESMO Congress 2026

Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026

TD Cowen Reiterates Buy on Revolution Medicines, Announces $250 Price Target

Revolution Medicines Begins Phase 3 Trial For Advanced Lung Cancer Treatment

Revolution Medicines (RVMD) Has an Approved Cancer Drug. Can Its $38 Billion Valuation Deliver?

Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer

Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $241

Revolution Medicines Stock In Focus After EU Drug Backing

Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow

William Blair Initiates Coverage On Revolution Medicines with Outperform Rating

Revolution Medicines’ RASONQUE™ (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer

EMA Says CHMP Has Recommended Granting A Marketing Authorisation In European Union For Rasonque (Daraxonrasib) For Metastatic Pancreatic Cancer

Needham Reiterates Buy on Revolution Medicines, Maintains $275 Price Target

Here's How Much $1000 Invested In Revolution Medicines 5 Years Ago Would Be Worth Today